Glaukos Reports Strong Q4 & Full-Year 2025 Results, Reaffirms 2026 Guidance, Advances Key Therapies

summarizeSummary

Glaukos Corporation announced robust financial results for Q4 and full-year 2025, with significant sales growth driven by key product launches, reaffirmed its 2026 revenue guidance, and provided positive updates on its pipeline.

check_boxKey Events

• Strong Sales Growth Reported

  Glaukos achieved record net sales of $143.1 million in Q4 2025, representing a 36% year-over-year increase, and full-year 2025 net sales of $507.4 million, up 32% from the prior year.

• 2026 Revenue Guidance Reaffirmed

  The company reaffirmed its net sales guidance for 2026, expecting revenues to be in the range of $600 million to $620 million.

• Non-Cash Impairment Charge Recorded

  A one-time, non-cash impairment charge of $112.9 million was recognized in Q4 2025, related to an acquired intangible asset associated with the transition from Photrexa to Epioxa.

• Key Product Pipeline Advancements

  Glaukos announced FDA approval for unlimited re-administration of iDose TR and commenced initial commercial launch plans for Epioxa following its October 2025 FDA approval, with drug availability expected in late Q1 2026.

auto_awesomeAnalysis

Glaukos Corporation reported strong financial performance for the fourth quarter and full fiscal year 2025, highlighted by substantial net sales growth. Fourth-quarter net sales increased 36% year-over-year to $143.1 million, while full-year net sales rose 32% to $507.4 million, driven by the successful adoption of iDose TR and broader Interventional Glaucoma initiatives. Despite a GAAP net loss of $133.7 million in Q4 2025, which included a one-time, non-cash impairment charge of $112.9 million related to the transition from Photrexa to Epioxa, the company's non-GAAP net loss improved significantly. Glaukos reaffirmed its 2026 net sales guidance of $600 million to $620 million, signaling confidence in continued growth. The company also provided positive updates on its robust pipeline, including FDA approval for unlimited re-administration of iDose TR and the commencement of commercial launch plans for Epioxa, further strengthening its position in ophthalmic pharmaceuticals and medical technology.